Advanced New Drug from Nektar with a Short-chain PEG
Nektar Therapeutics is advancing a new drug NKTR-181 to a Phase III clinical trial, which uses polymer chemistry to reach an elusive public health goal: relief from chronic pain with little potential for abuse.
This new drug approach is to covalently bond, through an ether linkage, a short-chain PEG to a five-ring morphinan. The resulting molecule can cross the blood-brain barrier slowly, preventing the “rush” that abusers seek.
BroadPharm provides a broad spectrum of monodispersed, high purity PEGylation reagents which can be used for conjugation of small molecules, peptides and proteins, resulting in prolonged stability, increased water solubility and lower immunogenicity.
Find the PEGylation reagents that’s just right for your project – PEG linkers.